Acetazolamide for Treatment Resistant Schizophrenia

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
Vishwajit Nimgaonkar, MD PhD
Study ID
NCT04887792
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • Acetazolamide — DRUG
    ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
  • Placebo — DRUG
    Identical gelatin capsules will be prepared by filling with inert excipients.

Study Details

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

Key Dates

Start date
Feb 1, 2022
Status verified
Apr 2026
Primary completion
Jun 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: Acetazolamide
    acetazolamide capsules
  • Active Comparator: Placebo
    Identical gelatin capsules

Primary Outcome Measure

Change in positive symptoms [ Time Frame: 24 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of PittsburghPittsburghPennsylvania15213
Maribeth A Wesesky, BPS
[email protected]
412-295-7017
Satish Iyengar, Ph.D. (SUB_INVESTIGATOR)
Konasale Prasad, M.D. (SUB_INVESTIGATOR)
Maribeth A Wesesky, BPS (SUB_INVESTIGATOR)
Ian Conner, M.D. (SUB_INVESTIGATOR)
Madhavi K Ganapathiraju, Ph.D. (SUB_INVESTIGATOR)
Roy KN Chengappa, M.D. (SUB_INVESTIGATOR)

Find similar trials in Pittsburgh, PA

By condition
Schizophrenia
By specialty
PsychiatryMental healthBehavioral health
By research site
University of Pittsburgh· Pittsburgh, PA

Related Studies